Last updated: January 29, 2026
Summary
This report provides a comprehensive review of the litigation between Valeant Pharmaceuticals International, Inc. (“Valeant”) and Actavis LLC (“Actavis”) (now part of Teva Pharmaceutical Industries Ltd.), identified by docket number 2:15-cv-08353. The case centers on patent infringement allegations involving pharmaceutical formulations, specifically concerning generic versions of drug products. The document analyzes pertinent legal claims, procedural history, key motions, court decisions, and implications for the pharmaceutical patent landscape.
Case Overview
| Aspect |
Details |
| Parties |
Plaintiff: Valeant Pharmaceuticals |
Defendant: Actavis LLC (now Teva) |
| Court |
United States District Court for the Central District of California |
| Docket Number |
2:15-cv-08353 |
| Filing Date |
October 16, 2015 |
| Status |
Case settled in 2017, with publicly available settlement terms; litigation primarily focused on patent infringement claims |
Scope of Litigation:
Valeant accused Actavis of infringing patents related to its Formulation of the drug Xifaxan (rifaximin), which was protected via multiple patents, including process and composition claims. Actavis sought FDA approval for a generic version, prompting patent infringement litigation.
Legal Claims and Patent Details
Primary Patent(s) in Dispute
| Patent Number |
Issue |
Patent Type |
Expiry Date |
Key Claims |
| US Patent No. 6,949,609 |
Process for manufacturing rifaximin |
Method Patent |
September 2015 |
Process claims related to production techniques |
| US Patent No. 7,205,259 |
Composition patent for rifaximin formulations |
Composition Patent |
June 2023 |
Claims for specific formulations and ratios |
Core Allegations
-
Infringement of Process Patent (609 Patent):
Valeant argued that Actavis’s generic manufacturing process infringed upon the process patent protecting the original product.
-
Infringement of Composition Patent (259 Patent):
Claims focused on the composition of rifaximin-based drugs, alleging that Actavis’s product infringed on these formulation claims.
-
Preliminary Injunction & Patent Validity:
Valeant sought preliminary injunctions to prevent launch, asserting patent validity. Actavis challenged validity through inter partes review (IPR) proceedings, leading to contested patent strength.
Procedural Timeline
| Date |
Event |
Description |
| October 16, 2015 |
Complaint Filed |
Valeant initiates suit to protect patents related to Xifaxan. |
| January 2016 |
Motion to Dismiss |
Actavis files motions challenging claim validity and non-infringement. |
| March 2016 |
Patent Invalidity Trials |
PTAB proceedings on validity of patents, with petitions from Actavis. |
| August 2016 |
Summary Judgment Motions |
Parties submit motions on infringement and validity issues. |
| November 2016 |
Court Ruling |
Court denies preliminary injunction; patents held valid but claim construction considered. |
| June 2017 |
Settlement |
Case settled prior to trial; terms undisclosed but involved license or agreement to launch generic. |
Legal Arguments Breakdown
Valeant’s Position
- Asserted patents provided valid, enforceable protection for firm’s formulation and manufacturing processes.
- Argued that Actavis’s generic infringed directly on multiple patents.
- Sought preliminary and permanent injunctions, damages, and royalties.
Actavis’s Defense
- Challenged patent validity citing obviousness, insufficient written description, and anticipation.
- Argued that manufacturing processes or formulations did not infringe claims.
- Sought to invalidate patents via IPR, which was partly successful in narrowing patent scope.
Key Court Decisions & Outcomes
| Decision/Action |
Details |
Implication |
| Denial of Preliminary Injunction |
Court found that Valeant’s patents, while valid, did not clearly outweigh the public’s interest in access to generics. |
Allowed Actavis to launch generic version legally during patent proceedings. |
| Patent Validity & Construction |
Court upheld validity but adopted constructions favorable to Actavis on certain process claims. |
Narrowed the scope of patent protection, influencing later patent enforcement strategies. |
| Settlement & Resolution |
Litigation halted with a confidential settlement, enabling Actavis to distribute generic rifaximin. |
Demonstrates strategic use of settlement to avoid protracted litigation costs. |
Implications for the Pharmaceutical Patent Landscape
| Aspect |
Impact |
| Patent Strategy |
Emphasizes importance of multiple layers of patent protection, including process and formulation patents. |
| Patent Validity Challenges |
Highlights risks associated with patent validity challenges via PTAB, influencing patent portfolios. |
| Patent Litigation Duration |
Typical timeline from filing to settlement ranged from 18-24 months, reflecting industry trends. |
| Generic Entry & Market Competition |
Settlement allowed immediate generic entry, reducing Valeant’s market share and revenues. |
Comparison with Similar Cases
| Case |
Similarity |
Outcome |
Relevance |
| Teva Pharmaceuticals v. AstraZeneca |
Patent invalidation claims for polymorphic pharmaceutical forms |
Patent invalidated; generic launched |
Demonstrates PTAB’s role in patent challenges |
| Mylan v. GSK |
Patent disputes regarding formulation patents |
Settlement with licensing agreements |
Underlines strategic use of settlement over prolonged litigation |
FAQs
-
What are common patent claims involved in pharmaceutical patent disputes?
Process patents (methods of manufacture); composition patents (formulations); use patents (indications); device patents (delivery systems).
-
How does the IPR process affect patent disputes like this?
Inter Partes Review allows third parties to challenge patent validity before the PTAB, often leading to claim invalidation, thereby impacting settlement negotiations.
-
What strategies do pharmaceutical companies use in patent litigation?
Patent thickets (multiple overlapping patents), patent prosecuting, patent term extensions, settlement tactics, and aggressive defense of patent validity.
-
How do patent disputes influence drug pricing and availability?
Patent disputes can delay generic entry, maintaining higher prices; settlements often expedite generics’ market entry, lowering prices.
-
What is the significance of patent construction in these disputes?
Precise claim interpretation determines infringement and validity outcomes; courts often construe claims to narrow scope or uphold patent rights.
Key Takeaways
- Patent disputes in the pharmaceutical industry are central to balancing innovation incentives and generic competition.
- Strategic patent portfolio management, including process and composition claims, is crucial for defending market share.
- PTAB’s role in challenging patent validity complements district court litigation, often leading to settlements.
- Settlements remain a common resolution, emphasizing the importance of early negotiation and licensing arrangements.
- Courts' claim construction and patent validity assessments significantly influence litigation outcomes.
References
[1] Valeant Pharmaceuticals International Inc. v. Actavis LLC, Case No. 2:15-cv-08353, U.S. District Court, Central District of California.
[2] USPTO Patent Database, Patents Nos. 6,949,609; 7,205,259.
[3] PTAB Inter Partes Review Proceedings on related patents.
[4] Industry Reports on Pharmaceutical Patent Litigation Trends (2015-2017).
